Skip to main content

Table 1 Baseline characteristics of subjects who completed the 24-week, double blind, placebo controlled portion of the study.

From: Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

 

Placebo (n = 11)

Curcumin 2 gm/day (n = 9)

Curcumin 4 gm/day (n = 10)

 

Age in years

70.2 (12.4)

76.7 (5.6)

75.3 (6.9)

P = 0.71

Gender, number of women (%)

6 (55%)

6 (67%)

7 (70%)

P = 0.74

Years of education (S.D.)

14.3 (2.5)

16.7 (1.3)

15.0 (2.7)

P = 0.08

Number on AchE-I's (%)

11 (100%)

7 (78%)

10 (100%)

P = 0.08

Number on memantine (%)

8 (73%)

7 (78%)

8 (80%)

P = 0.92

MMSE (S.D., range)

23.2 (2.3, 20-27)

21.4 (3.2, 17-28)

22.8 (3.4, 18-27)

P = 0.41

ADAS-Cog score (S.D.)

18.2 (4.9)

20.9 (7.4)

19.3 (3.4)

P = 0.64

NPI total score (S.D.)

8.5 (12.4)

8.9 (9.6)

11.7 (16.9)

P = 0.84

ADCS-ADL score (S.D.)

66.7 (3.6) (n = 10)

60.3 (10.9)

61.0 (8.4)

P = 0.18

  1. Note that ADCS-ADL score was not available on one subject in the placebo arm. AchE-I, acetylcholinesterase inhibitor; ADAS-Cog, Alzheimer's Disease Assessment Scale - Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study - Activities of Daily Living; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; S.D., standard deviation.